In addition to the rights set for in [Section 13.2.2], solely in the case of a Change in Control of ​ that occurs after ​ having completed all Initial Development Activities but before ​ having completed any Clinical Studies as referred to in [Sections 3.1.4 or 3.1.7]7], respectively, ​ shall have the right, in its sole discretion, to either require the Change in Control party to # promptly transfer such ongoing Clinical Studies to ​, or # promptly wind down and terminate such ongoing Clinical Studies in a manner that is permitted under Applicable Law.

In addition to the rights set for in [Section 13.2.2], solely in the caseevent of a Change in Control of ​ that occurs afterprior to ​ having completed all Initial Development Activities but before ​ having completed any Clinical Studies as referred to in [Sections 3.1.4 or 3.1.7]7], respectively,Activities, ​ shall have the right, in its sole discretion, to either # require the Change in Control party to complete the Initial Development Activities in accordance with the terms and conditions of this Agreement, or # promptlyassume and complete some or all of the unfinished Initial Development Activities; provided, that the Change in Control party shall be required to complete any Initial Development Activities that ​ elects not to assume and complete. If ​ elects to assume and complete any of the unfinished Initial Development Activities, then to the extent requested by ​ # ​ or the Change in Control party shall assign to ​ any or all Third Party agreements relating to such Initial Development Activities (including agreements with contract research organizations, clinical sites, investigators and manufacturing providers), and # ​ shall use Commercially Reasonable Efforts to perform the unfinished Initial Development Activities that ​ has elected to assume and complete under this [Section 13.2.2]. In the event ​ elects to assume any unfinished Initial Development Activities that involve Clinical Studies, ​ or the Change in Control party shall either transfer Control of such ongoing Clinical Studies to organization" data-ad-field-json='{"name":"Organization A","type":"organization","canGuess":{"name":false,"type":false}}'>​,Organization_ or # promptly wind downits designee and terminatecooperate with ​ to ensure a smooth and orderly transition thereof that will not involve any delay or disruption of such ongoing Clinical Studies in a manner that is permitted under Applicable Law.Studies. […​…].